{
    "clinical_study": {
        "@rank": "62197", 
        "arm_group": [
            {
                "arm_group_label": "Cohort A: Nivolumab", 
                "arm_group_type": "Experimental", 
                "description": "Nivolumab 3 mg/kg solution intravenous infusion over 60 minutes every two weeks until disease progression, unacceptable toxicity, or withdrawal of informed consent"
            }, 
            {
                "arm_group_label": "Cohort B: Nivolumab", 
                "arm_group_type": "Experimental", 
                "description": "Nivolumab 3 mg/kg solution intravenous infusion over 60 minutes every two weeks until 1 year (52 weeks).\nDiscontinue treatment and at progression, retreatment allowed"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to estimate the incidence and characterize the outcome of high\n      grade, select adverse events in subjects with advanced or metastatic NSCLC treated with\n      Nivolumab."
        }, 
        "brief_title": "A Safety Trial of Nivolumab (BMS-936558) in Subjects With Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Progressed During or After Receiving At Least One Prior Systemic Regimen (CheckMate 153)", 
        "completion_date": {
            "#text": "March 2019", 
            "@type": "Anticipated"
        }, 
        "condition": "Non Small Cell Lung Cancer (NSCLC)", 
        "condition_browse": {
            "mesh_term": [
                "Carcinoma, Non-Small-Cell Lung", 
                "Lung Neoplasms"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "For more information regarding BMS clinical trial participation, please visit\n        www.BMSStudyConnect.com\n\n        Inclusion Criteria:\n\n        1. Target Population\n\n          -  Subjects with histologically-or cytologically-documented NSCLC [squamous (SQ) or\n             nonsquamous (NSQ)] who present with Stage IIIB/Stage IV disease (according to version\n             7 of the International Association for the Study of Lung Cancer Staging Manual in\n             Thoracic Oncology), or with recurrent or progressive disease following multimodal\n             therapy (radiation therapy, surgical resection or definitive chemoradiotherapy for\n             locally advanced disease)\n\n          -  Subjects must have experienced disease progression or recurrence during or after at\n             least one systemic therapy for advanced or metastatic disease\n\n          -  First line therapy is defined as therapy used to treat advanced disease. Each\n             subsequent line of therapy is preceded by disease progression. A switch of an agent\n             within a regimen in order to manage toxicity does not define the start of a new line\n             of therapy\n\n          -  Maintenance therapy following platinum doublet-based chemotherapy is not considered\n             as a separate regimen of therapy\n\n          -  Subjects who received platinum-containing adjuvant, neoadjuvant or definitive\n             chemoradiation therapy given for locally advanced disease, and developed recurrent\n             (local or metastatic) disease within 6 months of completing therapy are eligible\n\n          -  Subjects with recurrent disease >6 months after platinum-containing adjuvant,\n             neoadjuvant or definitive chemoradiation therapy given for locally advanced disease,\n             who also subsequently progressed during or after a platinum doublet-based regimen\n             given to treat the recurrence are eligible\n\n          -  Subjects with progression or recurrent disease during or after Epithelial Growth\n             Factor Receptor (EGFR) or Anaplastic Lymphoma Kinase (ALK) tyrosine kinase inhibitor\n             (TKI) regimen are eligible\n\n          -  Experimental therapies when given as separate regimen are considered as separate line\n             of therapy\n\n          -  Eastern Cooperative Oncology Arm (ECOG) performance status (PS)\n\n          -  PS 0 to 1\n\n          -  PS 2\n\n        Exclusion Criteria:\n\n          1. Target Disease Exceptions\n\n               -  Subjects with active central nervous system (CNS) metastases are excluded\n\n               -  Subjects with carcinomatous meningitis\n\n          2. Medical History and Concurrent Diseases\n\n               -  Subjects with a history of interstitial lung disease\n\n               -  Subjects with active, known or suspected autoimmune disease\n\n               -  Subject whom participated in either arm of the following clinical trials\n                  CA209-017, CA209-057, CA209-026, and CA184-104 or received prior treatment with\n                  anti-programmed death 1 (PD-1) or anti-programmed death-ligand 1 (PDL1)\n                  experimental agents"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "780", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "February 14, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02066636", 
            "org_study_id": "CA209-153"
        }, 
        "intervention": {
            "arm_group_label": [
                "Cohort A: Nivolumab", 
                "Cohort B: Nivolumab"
            ], 
            "intervention_name": "Nivolumab", 
            "intervention_type": "Drug", 
            "other_name": "BMS-936558"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "May 30, 2014", 
        "link": [
            {
                "description": "BMS Clinical Trial Information", 
                "url": "http://ctr.bms.com/ctd/start.do"
            }, 
            {
                "description": "BMS clinical trial educational resource", 
                "url": "http://www.bms.com/studyconnect/Pages/home.aspx"
            }, 
            {
                "description": "Investigator Inquiry form", 
                "url": "http://www.bms.com/clinical_trials/Pages/Investigator_Inquiry_form.aspx"
            }, 
            {
                "description": "FDA Safety Alerts and Recalls", 
                "url": "http://www.fda.gov/MEDWATCH/safety.htm"
            }
        ], 
        "location": [
            {
                "contact": {
                    "last_name": "Samir Witta, Site 0006"
                }, 
                "facility": {
                    "address": {
                        "city": "Golden", 
                        "country": "United States", 
                        "state": "Colorado", 
                        "zip": "80401"
                    }, 
                    "name": "Mountain Blue Cancer Care Center"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Richard Levine, Site 0008"
                }, 
                "facility": {
                    "address": {
                        "city": "Titusville", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "32796"
                    }, 
                    "name": "Space Coast Cancer Center"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Grant Lewis, Site 0003"
                }, 
                "facility": {
                    "address": {
                        "city": "Savannah", 
                        "country": "United States", 
                        "state": "Georgia", 
                        "zip": "31405"
                    }, 
                    "name": "Summit Cancer Care"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Teresa Coleman, Site 0004"
                }, 
                "facility": {
                    "address": {
                        "city": "Thomasville", 
                        "country": "United States", 
                        "state": "Georgia", 
                        "zip": "31792"
                    }, 
                    "name": "Lewis Hall Singletary Oncology Center"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Justin Baker, Site 0002"
                }, 
                "facility": {
                    "address": {
                        "city": "Jackson", 
                        "country": "United States", 
                        "state": "Mississippi", 
                        "zip": "39202"
                    }, 
                    "name": "Jackson Oncology Associates, Pllc"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Kenneth Blankstein, Site 0009"
                }, 
                "facility": {
                    "address": {
                        "city": "Flemington", 
                        "country": "United States", 
                        "state": "New Jersey", 
                        "zip": "08822"
                    }, 
                    "name": "Hunterdon Regional Cancer Center"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "David Spigel, Site 0005"
                }, 
                "facility": {
                    "address": {
                        "city": "Nashville", 
                        "country": "United States", 
                        "state": "Tennessee", 
                        "zip": "37203"
                    }, 
                    "name": "The Sarah Cannon Cancer Center"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Ray D Page, Site 0007"
                }, 
                "facility": {
                    "address": {
                        "city": "Fort Worth", 
                        "country": "United States", 
                        "state": "Texas", 
                        "zip": "76104"
                    }, 
                    "name": "The Center For Cancer And Blood Disorders"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Phase IIIb/IV Safety Trial of Nivolumab (BMS-936558) in Subjects With Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Progressed During or After Receiving At Least One Prior Systemic Regimen", 
        "overall_contact": {
            "email": "Clinical.Trials@bms.com", 
            "last_name": "Recruiting sites have contact information. Please contact the sites directly. If there is no contact information, please email:"
        }, 
        "overall_contact_backup": {
            "last_name": "First line of the email MUST contain NCT# and Site #."
        }, 
        "overall_official": {
            "affiliation": "Bristol-Myers Squibb", 
            "last_name": "Bristol-Myers Squibb", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "March 2019", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Incidence for high grade (Grade 3-4 and Grade 5) treatment related select adverse events (AEs)", 
            "safety_issue": "Yes", 
            "time_frame": "Up to 100 days after last dose date (approximately up to 6.5 years)"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02066636"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Incidence for high grade (Grade 3-4 and Grade 5) select AEs", 
                "safety_issue": "Yes", 
                "time_frame": "Up to 100 days after last dose date (approximately up to 6.5 years)"
            }, 
            {
                "measure": "Median time to onset and median time to resolution (Grade 3-4)", 
                "safety_issue": "Yes", 
                "time_frame": "Up to 100 days after last dose date (approximately up to 6.5 years)"
            }, 
            {
                "description": "Immune modulating medication (e.g. corticosteroids, Infliximab, Cyclophosphamide, intravenous immune globulin (IVIG), and Mycophenolate Mofetil)", 
                "measure": "Percentage of subjects who received immune modulating medication or hormonal replacement therapy, percentage of subjects who received \u226540 mg Prednisone equivalents, total duration of all immune modulating medications given for select event", 
                "safety_issue": "Yes", 
                "time_frame": "Up to 100 days after last dose date (approximately up to 6.5 years)"
            }
        ], 
        "source": "Bristol-Myers Squibb", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Bristol-Myers Squibb", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "February 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}